The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study
- 15 April 2011
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 26 (10) , 1851-1858
Abstract
Cognitive impairment can occur at all stages of Parkinson's disease. Rasagiline is a selective monoamine oxidase type‐B inhibitor that enhances central dopaminergic transmission. Dopamine is thought to be involved in certain cognitive processes such as working memory. We assessed the effects of rasagiline on cognitive deficits in cognitively impaired, nondemented patients with Parkinson's disease. This was a randomized, double‐blind, placebo‐controlled prospective study. Patients with Parkinson's disease receiving stable dopaminergic treatment were assigned to receive rasagiline 1 mg/day or placebo for 3 months. Patients were eligible if they had impairment in 2 of 4 cognitive domains (attention, executive functions, memory, visuospatial functions) in the screening neuropsychological tests, yet did not fulfill criteria for Parkinson's disease dementia. Fifty‐five patients were randomized; 48 patients completed the study. Patients in the rasagiline group showed significant improvement in digit span–backward compared with the placebo group (P = .04), with trends favoring rasagiline in digit span total and digit‐ordering tests. Verbal fluency total score showed a significant difference in favor of rasagiline (P = .038), with trends favoring rasagiline in semantic fluency test and Stroop spontaneous corrections. The composite cognitive domain Z scores revealed a significant difference in favor of rasagiline compared with placebo in the attentional Z score (P < .005). There were no significant differences between the 2 groups in the other cognitive tests or cognitive domain Z scores. The monoamine oxidase type‐B inhibitor rasagiline may exert beneficial effects on certain aspects of attention and executive functions in nondemented patients with Parkinson's disease with cognitive impairment. © 2011 Movement Disorder SocietyKeywords
This publication has 30 references indexed in Scilit:
- Rasagiline improves learning and memory in young healthy ratsBehavioural Pharmacology, 2010
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's DiseaseNew England Journal of Medicine, 2009
- Monoamine oxidase inactivation: From pathophysiology to therapeuticsAdvanced Drug Delivery Reviews, 2008
- Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodiesJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Memory and executive function impairment predict dementia in Parkinson's diseaseMovement Disorders, 2002
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.Journal of Neurology, Neurosurgery & Psychiatry, 1992
- The effect of age of disease onset on neuropsychological performance in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1988
- Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and CortexAnnual Review of Neuroscience, 1986
- Development and validation of a geriatric depression screening scale: A preliminary reportJournal of Psychiatric Research, 1982
- ParkinsonismNeurology, 1967